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Recombinant measles nucleoprotein (N) and synthetic peptides spanning the length of the N-protein-coding region were
used with a proliferation assay to identify human T-cell epitopes in vaccinated and naturally infected adults. A number of
epitopes were mapped to specific regions of the measles virus N. The proliferative response of at least two donors was
mediated by CD4/ T cells in association with HLA DR antigens. Over 70% of all donors tested responded to peptides
representing amino acids 271–290, 367–386, 400–420, and 483–502, suggesting that these peptides may be broadly
recognized within an HLA diverse population. The most frequently recognized T-cell epitopes in both naturally infected and
vaccinated donors were located in the genetically heterogeneous carboxy-terminal half of the N. Analysis of patterns of
peptide reactivity among vaccinated and naturally infected subjects identified several regions of potential difference between
these two groups. Peptides 221–240 and 237–256 were recognized among 100% of naturally infected donors but among
only 37.5% of vaccinated donors and therefore may be of further interest in studies to investigate induction of lifelong
versus transient immunity to measles. Use of chimeric molecules containing multiple well-characterized T- and B-cell
epitopes or genetic alteration of attenuated vaccine virus to enhance critical T-cell responses may eventually lead to the
development of a vaccine candidate that can more closely model the patterns of immune response elicited by wild-type
virus. q 1997 Academic Press
INTRODUCTION bility that the attenuated vaccine virus may induce a re-
sponse that differs in breadth and/or magnitude from the
Measles is a severe, highly communicable, viral infec-
response to wild-type virus and therefore wanes more
tion that remains a significant health problem in devel-
rapidly. In addition, although measles virus is considered
oping countries. Vaccination programs have resulted in a
a monotypic virus, antigenic variation has been de-
major reduction in the incidence of measles in developed
scribed for wild-type strains (Giraudon et al., 1988; Tamin
countries, but periodic outbreaks and sustained epidem-
et al., 1994). The effect of this wild-type variation on im-
ics continue to occur worldwide. Measles cases have
mune protection is unclear. Furthermore, host factors
been confirmed in vaccinated subjects with documented
such as HLA haplotype may predispose some individuals
seroconversion, indicating that the current live attenu-
to a suboptimal immune response to the vaccine strain.
ated vaccine does not always provide lifelong protection Regardless of the cause, the occurrence of vaccine fail-
as does natural measles infection (Mathias et al., 1989; ures (both primary and secondary) in the general popula-
Markowitz et al., 1990). Antibody levels that develop after tion poses an impediment to the ultimate goal of measles
natural infection remain relatively stable; however, vac- eradication.
cine-induced antibody levels have been shown to decline Measles virus infection is associated with a range of
over time in some individuals following vaccination and temporary immunologic abnormalities, including sup-
even revaccination (Krugman, 1983; Markowitz et al., pression of in vivo delayed-type hypersensitivity (DTH)
1990; Ward et al., 1995). Potential explanations for the skin responses, increased plasma IgE, decreased in vitro
observed secondary vaccine failures include the possi- proliferative responses to mitogens, decreased natural
killer activity, and altered in vitro cytokine production
(Griffin et al., 1994). This measles-associated immuno-1 Human experimentation guidelines of the authors’ institution were
followed, the research protocol was approved by the Centers for Dis- suppression has complicated efforts to characterize the
ease Control and Prevention Institutional Review Board, and written cell-mediated immune response to infectious measles
informed consent was obtained from participants. virus in vitro. Proliferative responses to measles virus2 To whom correspondence and reprint requests should be ad-
antigens have generally been difficult to detect (Griffindressed at Centers for Disease Control and Prevention, MS C-22,
et al., 1994; Rose et al., 1984; Krause et al., 1980). TheDVRD, REVB, 1600 Clifton Road NE, Atlanta, GA 30333. Fax: (404) 639-
4187. use of cloned recombinant measles antigens or synthetic
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peptides provides a way to examine cellular responses of the measles virus N. Analysis of patterns of peptide
reactivity among vaccinated and naturally infected sub-while circumventing problems associated with measles
virus-induced suppression. jects identified several regions of potential difference be-
tween these groups. In both vaccinated and naturallyCell-mediated immunity appears to play a critical role
in both recovery from primary measles infection and pro- infected individuals, most HLA cross-reactive peptides
were located in the C-terminal half of the N molecule.tection from subsequent disease. Children with specific
defects in T-cell function often develop severe measles
with fatal secondary bacterial or viral complications, MATERIALS AND METHODS
whereas children who have congenital agammaglobuli-
Human subjectsnemia, when given appropriate medical support, respond
to measles with the usual sequence of symptoms and Vaccinated adults. Of eight healthy adult volunteers who
subsequently develop immunity to reinfection (Good and received measles, mumps, rubella vaccine (MMRII) (Merck
Zak, 1956; Burnet, 1968; Kernahan et al., 1987; Markowitz Laboratories) as infants, six (donors A, B, C, E, G, and H)
et al., 1988). Despite the obvious importance of cell-medi- had never had natural measles virus infection and two
ated immunity in measles, few data are available on T- (donors D and F) had contracted natural measles infection
cell epitopes of measles virus proteins recognized by as children. All adult volunteers were revaccinated with
humans after infection or vaccination. Systematic evalua- monovalent measles vaccine (Attenuvax) after giving in-
tion of the cellular (proliferative) immune responses of formed consent. Ten days postvaccination, donors were
both vaccinated and naturally infected individuals will lymphocytophoresed and PBMC were isolated by density
not only identify potentially important measles T-cell epi- interface centrifugation over lymphocyte separation me-
topes, but also may provide insight into the immune dium (Organon Teknika Corp., Durham, NC). The mononu-
mechanisms needed for lifelong versus transient protec- clear cell layer was isolated and washed three times with
tion and help to develop correlates of protection that can Hank’s balanced salt solution (HBSS). PBMC were frozen
be used in the evaluation of candidate measles vaccines. in aliquots in a mixture of 90% fetal calf serum (Hyclone
Measles nucleoprotein (N) was chosen for study be- Laboratories, Inc., Logan, UT) and 10% dimethylsulfoxide,
cause of the established importance of this protein in using a rate programmable freezer (Forma Scientific, Mari-
both humoral and cellular immune responses. Measles etta, OH), and stored in liquid nitrogen to provide a uniform
N is the most abundantly expressed viral protein during source of materials for further analysis. TT vaccine history
measles virus infection, and antibodies against N are the is unknown in these donors.
most prevalent and the first to appear in the serum during Naturally infected adults. Six adult volunteers who had
acute measles virus infection (Norrby and Gollmar, 1972; been naturally infected with measles 50 to 80 days pre-
Graves et al., 1984). Both cytotoxic T-lymphocyte (CTL) viously were lymphocytophoresed after giving informed
and proliferative T-lymphocyte responses specific for consent. These individuals were involved in well-charac-
measles N have been detected in humans (Jacobson et terized outbreaks in New Jersey and Colorado (CDC,
al., 1987/1988; Ilonen et al., 1990). Murine CTL epitopes 1994a,b). Donor I had been vaccinated at 15 months of
have been identified on the measles N, linked to a T- age and again 10 days before rash onset. Donor J had
helper epitope, and used to induce measles virus-spe- been vaccinated as an infant and 4 years prior to rash
cific CTL in the mouse (Beauverger et al., 1994; Partidos onset. Donor M had been vaccinated at 15 and 18 months
et al., 1996). In addition, measles virus N has been impli- of age. Donor N was vaccinated 2 days before rash on-
cated in protection against measles-induced encephali- set. Donors K and L had never been vaccinated. TT vac-
tis in the mouse (Bankamp et al., 1991). Interestingly, the cine history is unknown in these donors. Lymphocyto-
measles N is the most genetically heterogeneous of the phoresis units were shipped on wet ice overnight, and
measles proteins (Taylor et al., 1991; Rota et al., 1994; PBMC were isolated and frozen as described above.
Rima et al., 1995). Within the C-terminal 450 nucleotides
of the N, variability between wild-type and vaccine strains Peptides
of measles virus can exceed 10% (Rota et al., 1994; Rima
et al., 1995; Taylor et al., 1991). Peptide sequences were based on the predicted amino
acid sequence of the Edmonston strain (Rozenblatt et al.,In this study, human proliferative responses to purified
measles virus N and 32 N peptides encompassing the 1985). Peptides were prepared at the Centers for Disease
Control and Prevention’s Biotechnology Core Facility byN coding region were examined in eight recently vacci-
nated individuals and six recently naturally infected indi- solid-phase peptide synthesis, using an Applied Biosys-
tems 430A peptide synthesizer. Peptides (17–21 residuesviduals. Lymphocyte stimulation of peripheral blood mo-
nonuclear cells (PBMC) was performed in the absence in length) were purified to 90% and their compositions
were confirmed by amino acid analysis. Overlaps betweenof cycles of antigenic stimulation in vitro. A number of
human T-cell epitopes were mapped to specific regions peptides ranged from 0 to 9 amino acids. The quality of
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peptide synthesis was assessed by high-pressure liquid (5 1 104) in the presence of medium, purified baculovirus
expressed N protein (Intracel Corp., Cambridge, MA), orchromatography and capillary electrophoresis.
N peptides. After 6 days in culture, wells were pulsed
Cell preparation with [3H]thymidine and harvested as described above.
Frozen PBMC were thawed and washed three times
Monoclonal antibody blocking assays
in RPMI complete medium (RPMI 1640 supplemented
with 1% fresh L-glutamine, 10 units per milliliter of penicil- Monoclonal antibodies to HLA DR (clone L243), HLA DQ
(clone IVD12), HLA DR, DP, DQ (clone IVA12), HLA A, B, Clin/streptomycin, and 10 mM HEPES buffer) containing
10% heat-inactivated fetal bovine serum. Viability of (clone W6/32), and an antibody specific for mouse I-ab
(clone 25-9-17SII) were purchased from Spring Valley Labo-PBMC was determined by trypan blue exclusion. PBMC
were separated into enriched T-cell and enriched mono- ratories (Sykesville, MD) as purified IgG derived from hy-
bridoma culture supernatants. The monoclonal antibodiesnuclear cell fractions by T-cell rosetting with neuramini-
dase-treated sheep red blood cells (SRBC) (Kanof, 1996). used in these studies have been used extensively to block
T-cell proliferation (Celis et al., 1988; Flomberg et al., 1989;The mononuclear cell-enriched fraction was resus-
pended at 1 1 106 cells/ml in RPMI complete medium Weyland and Goronzy, 1990; Hoffman et al., 1993; Ito et al.,
1993; McCarthy et al., 1993; Simons et al., 1993; Garlie andcontaining 10% heat-inactivated human AB serum and
g-irradiated (2000 R) for use as antigen-presenting cells. Eckels, 1994; Plebanski and Burtles, 1994; Yoshino et al.,
1994). L243 (anti-HLA DR) reacts with a nonpolymorphicThe enriched T-cell fraction was resuspended at 2 1 106
in RPMI complete medium containing 10% heat-inacti- HLA DR epitope (Lampson and Levy, 1980; Brodsky, 1984;
Robbins et al., 1987) and does not cross-react with HLA-vated human AB serum.
DQ or HLA-DP molecules (Levacher et al., 1990). W6/32
Proliferation assay produces a monoclonal antibody specific for a monomor-
phic determinant on the HLA-A, B, and C glycoproteinsMicrocultures (200 ml) containing 1 1 105 enriched T
(Brodsky and Parham, 1982). IVD12 produces a monoclonalcells and 5 1 104 irradiated (2000 R) antigen-presenting
antibody that detects a DQw3-like determinant on DQ mole-cells were stimulated with 100 ml of antigen preparation
cules (Giles et al., 1983; Radka et al., 1987). IVA12 producesin 96-well flat-bottomed plates (Costar Corp., Cambridge,
a monoclonal antibody reactive with HLA-DR, -DP, andMA). Full-length baculovirus expressed N protein (⁄99%
-DQ (Shaw et al., 1985).pure) was provided by Intracel Corp. (Issaquah, WA) and
Monoclonal antibodies to major histocompatibilityused at 3 mg/well. Preservative- and adjuvant-free teta-
complex (MHC) class I and class II molecules (3–30 mg/nus toxoid (TT, Connought Laboratories Ltd., Swiftwater,
ml) were added to replicate microcultures containing 1PA) was used at 6 leucoflocculation units (Lf) per well. All 1 105 enriched T cells and 5 1 105 irradiated antigen-antigens were diluted in RPMI complete medium without
presenting cells that were stimulated with purified N pro-serum. Peptides were used at a final concentration of 10
tein (15 mg/ml) or peptide (10 mM). Antibody-blockingmM. Assays were conducted using six replicates per test
studies were conducted using six replicates per testgroup for TT and N and 6–12 replicates per test group for
group. After 6 days in culture, wells were pulsed withcontrol and peptide stimulations. Cultures plus antigens
[3H]thymidine and harvested as described above.were incubated at 377 in 5% CO2 in humidified air for 7
days. [3H]Thymidine (0.5 mCi per well, 6.7 Ci/mmol; Du-
HLA typing
pont, NEN Biotechnology Systems, Wilmington, DE) was
added for the final 18 hr of culture. Cells were harvested MHC typing was performed on peripheral blood leuko-
cytes obtained from whole blood or frozen cell prepara-onto glass fiber filters, using a 96-well Packard Matrix
harvesting system (Packard Instrument Corp., Meriden, tions by the Emory University Hospital HLA laboratory
(Atlanta, GA), using sequence-specific primer polymer-CT). The amount of incorporated radioactivity was deter-
mined by direct beta counting, using a Packard Matrix ase chain reaction.
9600 direct beta counter. Stimulation indices of ⁄3 were
Similarity plot for the predicted N proteins of 50 wild-considered to represent significant responses.
type measles strains
CD4/ cell enrichment studies
Sequence data were analyzed using version 8.0 of the
Wisconsin Sequence Analysis Package, Genetics Com-Anti-human CD8 magnetic beads (Dynal A. S, N-0212
Oslo, Norway) were used to deplete T-cell-enriched pop- puter Group (Deveraux et al., 1984). The PLOTSIMILAR-
ITY program was used to calculate and display a runningulations of CD8/ cells as described by the manufacturer.
CD4/ enriched cells were ⁄95% pure when assessed average of the similarity within a 5-nucleotide window
among aligned nucleoprotein sequences. The analysis ofby flow cytometry. CD4/-enriched T cells (1 1 105) were
cocultured with irradiated autologous mononuclear cells the nucleoprotein gene sequences from multiple, diverse
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TABLE 1 experiment is shown in Fig. 1. Data presented are mean
[3H]thymidine uptake{ standard error of the mean (SEM) ofHLA DR and DQ Antigen Expressiona
six replicates. During the course of preliminary experiments
Donor DR DQ using PBMC from vaccinated donors, it was noted that
SEM values for peptides, but not for TT or N, were high,
A 13, 14 5, 6 most likely due to the random distribution of low numbers
B 13, 13 6, 6
of specific responding T cells among replicate wells. In anC 13, 17 2, 7
effort to minimize standard errors, 12 replicate wells perD 17, 17 2, 2
E 1, 13 7, 5 peptide were used in subsequent experiments. Initial ex-
F 1, 1 5, 5 periments with vaccinated donors were done using a range
G 1, 13 5, 6 of peptide concentrations (20, 10, 5, 1, and 0.1 mM). Prolifer-
H 1, 13 5, 6
ation was seen over the range of 1–20 mM, with optimalI 1, 15 5, 6
proliferation generally at 10 mM. Subsequent experimentsJ 1, 13 5, 6
K 1, 17 2, 5 were performed using a 10 mM peptide concentration. In
L 7, 16 9, 5 addition, as noted by other investigators (Simons et al.,
M 1, 18 5, 6 1993), peptide responses sometimes varied slightly be-
N 17, 7 2, 2
tween experiments on cells from the same donor; therefore,
stimulation indices from three separate experiments pera MHC typing was performed on buffy coats obtained from whole
blood or frozen cell preparations by the Emory University Hospital HLA donor were averaged to give a consensus proliferation pro-
laboratory using sequence-specific primer polymerase chain reaction. file (Tables 3 and 4). Average stimulation indices of ⁄3
were considered significant. The variability seen between
experiments on the same donor was seen primarily for
wild-type measles viruses has been described previously responses that were near the cutoff of 3. Less variability
(Rota et al., 1994, 1996). was seen with peptides that gave strong (SI 5) prolifera-
tive responses. For clarity stimulation indices of3 are not
RESULTS shown.
Proliferative response to purified baculovirus Proliferative response of vaccinated donors to
expressed N protein measles N peptides
A number of peptides containing T-cell epitopes wereHuman volunteers A through H were vaccinated with
identified in measles-vaccinated individuals (Table 3).monovalent measles vaccine and lymphocytophoresed
10 days postvaccination. Human volunteers I through N
had documented natural measles virus infection 50 to 80 TABLE 2
days prior to lymphocytophoresis. To assess whether
Proliferative Response to Purified Measles Nucleoproteinameasles N-specific T cells were present in these donors,
HLA-typed PBMC (Table 1) were separated into a T-cell- Donor Medium TT b NP c
enriched fraction and an enriched mononuclear cell frac-
A 65 { 7 15,693 { 764 (241) 7,337 { 945 (113)tion, using neuraminidase-treated SRBC. Microcultures
B 50 { 15 12,618 { 1291 (252) 6,752 { 966 (135)containing T cells and irradiated mononuclear cells were
C 120 { 26 1,626 { 676 (14) 2,717 { 1141 (23)stimulated with purified baculovirus-expressed measles D 224 { 56 5,792 { 1208 (26) 3,949 { 440 (18)
N protein, antigen diluent (negative control), and TT (posi- E 74 { 7 15,339 { 1022 (207) 7,569 { 375 (102)
tive control). All donors gave strong proliferative re- F 162 { 16 16,670 { 889 (103) 8,921 { 1987 (55)
G 529 { 129 19,032 { 2822 (36) 14,087 { 3302 (27)sponses to TT, with stimulation indices ranging from 14
H 243 { 107 29,007 { 5001 (119) 14,569 { 1866 (60)to 252 compared with control stimulated cultures (Table
I 83 { 30 8,675 { 563 (108) 4,443 { 725 (53)2). In addition, all donors gave significant proliferative J 28 { 2 3,359 { 314 (119) 1,728 { 322 (62)
responses to purified baculovirus-expressed N protein, K 35 { 3 4,310 { 142 (123) 1,790 { 174 (51)
with stimulation indices ranging from 18 to 135 over con- L 70 { 30 5,290 { 256 (76) 3,799 { 191 (54)
M 76 { 10 8,259 { 563 (109) 7,019 { 643 (92)trol stimulated cultures. Proliferative responses to mea-
N 40 { 4 705 { 72 (18) 1,218 { 154 (30)sles N protein were dose dependent (data not shown)
and optimal at 3 mg/well. a All values are means{ SEM. Data are for replicates of six microcul-
tures (200 ml) containing enriched T cells (1 1 105 per well), irradiated
Peptide proliferation assay autologous antigen-presenting cells (5 1 104 per well), and antigen or
medium (100 ml). Results are expressed as mean uptake of [3H]thymi-
The proliferative response to a series of 32 peptides that dine per well. Stimulation indices are indicated in parentheses.
span the entire length of the measles virus N protein coding b Tetanus toxoid (TT) was used at a concentration of 6 Lf/well.
c Measles N was used at a concentration of 3 mg/well.region was assessed initially in donor E. A representative
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FIG. 1. Representative proliferation experiment. PBMC (donor E) were separated into enriched T-cell and enriched mononuclear cell fractions by
T-cell rosetting. Enriched T cells (1 1 105) were cocultured with irradiated autologous mononuclear cells (5 1 104) in the presence of medium
(control), purified baculovirus-expressed N protein, or a series of 32 peptides that span the entire length of the measles virus N protein. Data are
shown as mean [3H]thymidine uptake { SEM of six replicates. The response to medium alone was 74 { 7 and 15,339 { 1022 to purified N protein.
Stimulation indices of 3 are reported above the corresponding bars.
Positive stimulation indices ranged from 3.0 to 18.4. 221–240 and 237–256 while only 37.5% of vaccinated
donors had responses to these peptides.Some donors responded to a broad range of peptides
(donors B, G, and H), while others responded to a limited
number (A, D, E, and F). Six of eight vaccinated donors Immunologic characterization of the proliferative
response to measles N protein and N peptideswith no single MHC class II antigen in common re-
sponded to peptide 271–290 while five of eight recently
In an effort to determine if the proliferative responsevaccinated donors with no single MHC class II antigen
to measles N protein and N peptides was dependent onin common responded to peptides 1–17, 51–70, 400–
the presence of CD4/ or CD8/ cells, the enriched T-cell420, 417–436, and 509– 525, suggesting that these pep-
fraction from donors A and E was depleted of CD8/tides may be broadly recognized within an HLA diverse
cells, using magnetic beads coated with a monoclonalpopulation. Most epitopes that stimulate 50% or more of
antibody specific for CD8. No inhibition of proliferationthe donors are located in the carboxy-terminal half of the
was observed upon depletion of CD8/ cells, suggestingN protein molecule.
that the proliferative response of these two individuals
is class II restricted (data not shown). Because of theProliferative response of naturally infected donors to
abundance of lymphocytes obtained from donors A andmeasles N peptides
E, these donors were selected for additional experiments
in which monoclonal antibodies to HLA class II mole-Like vaccinated donors, naturally infected measles do-
nors responded to a range of peptides (Table 4). Positive cules and a control antibody (anti-Iab) were used to block
antigen presentation and define HLA-restricting ele-stimulation indices ranged from 3.0 to 38.4. Six of six
naturally infected donors responded to peptides 221– ments involved in presentation of measles N protein and
N peptides. Antibodies were titrated to determine optimal241, 237–256, 367–386, 400–420, and 483–502, while
five of six donors responded to peptides 202–220, 271– blocking concentration and minimize nonspecific inhibi-
tion. As shown in Fig. 2A (donor A), a monoclonal anti-290, 287–303, 335–354, and 433–452. As seen with vac-
cinated donors, most cross-reactive epitopes are located body specific for HLA DR inhibited proliferation to N pro-
tein (50%). Antibodies to HLA DR, DP, DQ, and HLA DQin the carboxy-terminal region of the N protein molecule.
Interestingly, none of the naturally infected donors had gave some inhibition of proliferation to N protein (22 and
16%, respectively), and no nonspecific inhibition wasproliferative responses to peptide 1–17, whereas five
of eight vaccinated donors had a significant response. seen. Three immunodominant peptides recognized by T
cells from donor A were then examined in an effort toFurther comparison of the responses of vaccinated ver-
sus naturally infected subjects indicated that 100% of determine the HLA molecule responsible for presenta-
tion. As seen in Fig. 3A, proliferative responses to pep-naturally infected donors had responses to peptides
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TABLE 3
Proliferative Response of Vaccinated Donors to Measles Virus Nucleoprotein Peptides
Donor (stimulation indices) a
No. positive
Peptide A B C D E F G H donors b
1 –17 3.0 6.6 3.0 3.3 3.0 5 c
17 –36 0
34 –53 0
51 –70 4.2 6.0 5.6 4.4 6.7 5 c
67 –86 3.7 1
83 –102 4.9 5.1 3.1 4.2 4 c
101 –120 3.0 5.7 4.1 3
117 –135 0
133 –152 0
151 –170 0
167 –184 6.5 5.2 2
185 –204 5.2 5.7 3.7 3
202 –220 3.0 4.3 8.4 3
221 –240 3.5 3.6 3.3 3
237 –256 7.0 10.4 8.0 3
254 –273 3.4 1
271 –290 3.0 5.5 7.3 3.0 18.4 6.1 6 c
287 –303 3.1 3.5 6.3 3
303 –320 3.2 4.2 5.6 6.6 4 c
319 –338 3.5 7.5 5.8 3
335 –354 5.8 10.0 7.4 6.5 4 c
351 –370 4.9 1
367 –386 7.0 4.8 6.5 7.6 4 c
384 –403 4.1 3.0 4.5 3
400 –420 3.5 3.1 4.5 5.8 5.5 5 c
417 –436 3.7 8.8 3.5 5.2 3.5 5 c
433 –452 3.2 3.4 4.5 9.2 4 c
451 –470 5.0 4.9 3.3 3
467 –484 8.1 4.1 3.5 8.7 8.8 5 c
483 –502 9.4 3.5 6.7 10.2 4 c
501 –517 3.6 3.5 8.6 3
509 –525 5.4 4.1 12.8 6.3 5.0 5 c
a Data shown represent average stimulation indices from three separate experiments. For clarity, only stimulation indices ⁄3 are shown. The
induced proliferative responses of 12 replicate wells per peptide were measured by [3H]thymidine incorporation after 7 days. Peptide concentration
was 10 mM.
b Number of positive donors represents the total number of donors responding to individual peptides with an average stimulation index of ⁄3.
c Peptides that stimulated 50% or more of the donors.
tides 83–102, 271–290, and 509–525 were predomi- cule is responsible for presentation of these peptides.
Peptide 167–184 was not inhibited by antibody directednantly inhibited by antibody specific for HLA DR, sug-
gesting that HLA DR presents at least three N peptides against either DR or DQ and therefore it is unclear what
molecule may be responsible for presentation of thisto T cells from donor A. With respect to donor E, antibody
specific for HLA-DR resulted in 41% inhibition of N prolif- peptide.
eration over the 39% inhibition seen with the control anti-
body (Fig. 2B). No specific inhibition was seen with anti- DISCUSSION
body to HLA DQ or HLA A, B, or C. Twenty percent spe-
cific inhibition was seen with antibody to HLA DR, DP, The present study is the first to systematically map
human T-cell epitopes on the measles virus N. Recombi-and DQ, presumably due to antibody directed against
HLA DR. Three immunodominant peptides, 51–70, 167– nant measles N and synthetic peptides spanning the
entire length of the N protein coding region were used184, and 400–420, recognized by donor E were exam-
ined as above to determine MHC specificity (Fig. 3B). to identify potential determinants of cell-mediated immu-
nity to the virus in both vaccinated and naturally infectedPeptides 51–70 and 400–420 were predominantly inhib-
ited by antibody to HLA DR, suggesting that the DR mole- humans.
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TABLE 4
Proliferative Response of Naturally Infected Donors to Measles Virus Nucleoprotein Peptides
Donor (stimulation indices) a
No. positive
Peptide I J K L M N donors b
1 –17 0
17 –36 7.9 11.9 2
34 –53 6.9 7.7 2
51 –70 8.7 14.0 3.2 3 c
67 –86 0
83 –102 6.8 10.2 2
101 –120 9.6 8.1 3.0 3 c
117 –135 8.4 5.3 2
133 –152 5.5 7.1 2
151 –170 8.2 1
167 –184 0
185 –204 9.6 3.7 17.0 3.5 4 c
202 –220 11.5 3.4 4.6 5.7 3.3 5 c
221 –240 28.9 5.2 6.1 11.6 5.7 8.0 6 c
237 –256 30.1 3.4 6.6 12.1 8.0 7.9 6 c
254 –273 3.2 1
271 –290 28.4 5.1 5.3 11.8 4.5 5 c
287 –303 22.7 3.6 12.4 4.0 3.1 5 c
303 –320 17.7 4.4 12.5 3.3 4 c
319 –338 5.8 1
335 –354 24.7 3.0 8.0 13.2 7.7 5 c
351 –370 7.2 4.3 2
367 –386 25.2 5.0 4.9 9.0 5.1 3.1 6 c
384 –403 13.3 3.8 9.6 3 c
400 –420 10.1 4.8 3.5 6.2 4.5 5.6 6 c
417 –436 7.0 6.4 2
433 –452 14.6 3.0 11.4 5.7 3.0 5 c
451 –470 31.0 15.6 3.2 3 c
467 –484 18.6 3.9 17.6 3 c
483 –502 38.4 5.1 4.8 12.5 7.1 9.3 6 c
501 –517 11.7 12.3 3.2 3 c
509 –525 15.9 12.9 3.7 3 c
a Data shown represent average stimulation indices from three separate experiments. For clarity only stimulation indices ⁄3 are shown. The
induced proliferative responses of 12 replicate wells per peptide were measured by [3H]thymidine incorporation after 7 days. Peptide concentration
was 10 mM.
b Number of positive donors represents the total number of donors responding to individual peptides with an average stimulation index of ⁄3.
c Peptides that stimulated 50% or more of the donors.
Measles N has an established role in both humoral length of a protein has been noted by other investigators
in both bacterial and viral systems (Chaye et al., 1993;and cellular immune responses to measles virus. All do-
nors tested in this study gave significant proliferative Roche et al., 1996).
Inhibition studies using monoclonal antibodies spe-responses to purified N, underscoring the role of the N
as a key immunogen in measles virus immunity. Both cific for human HLA molecules indicated that the prolifer-
ative responses of at least two donors to purified N werevaccinated and naturally infected donors displayed var-
ied patterns of peptide-specific lymphoproliferative re- MHC class II restricted. Inhibition was seen predomi-
nantly in response to antibody specific for HLA DR, al-sponses, an observation that is consistent with the diver-
sity of HLA class II molecules represented. In general, though some inhibition was detected after treatment with
antibody to DQ or antibody specific for DR, DP, and DQ.individuals with the strongest proliferative responses to
purified N responded to the greatest numbers of pep- In keeping with this observation, proliferative responses
of these same donors to five of six peptides examinedtides. A number of individuals, both vaccinated and natu-
rally infected, were observed to respond to over 50% of appeared to be DR restricted.
T-cell determinants of the measles N were distributedthe 32 peptides tested. Broad peptide reactivity in which
humans responded to almost all peptides along the along most of the length of the molecule in both vacci-
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cine peptides. Lack of immune recognition of critical
wild-type T-cell epitopes in vaccinated donors may help
to explain the susceptibility of some vaccinated individu-
als to reinfection with measles virus. Some human immu-
nodeficiency virus (HIV) variants have been shown to
escape recognition by human CTL and may provide a
mechanism by which HIV can evade immune surveil-
lance (Phillips et al., 1991).
Previous studies identified three N peptides, 210–218,
226–234, and 340–348, as being capable of inducing
measles-specific CTL in PBMC from measles-seroposi-
tive individuals (Nanan et al., 1995). These peptides were
selected for synthesis by screening the N sequence for
HLA-A2.1-binding motifs. In the present study, peptides
that encompass the previously identified CTL epitopes
210–218, 226–234, and 340–348 were all strong prolifer-
ative epitopes recognized by 57, 64, and 64% of total
donors, respectively. All three of these peptides were
recognized by a greater percentage of naturally infected
donors than vaccinees and therefore could be of poten-
FIG. 2. Antibodies to HLA class II molecules inhibit proliferation to tial importance in maintaining measles immunity.
measles N protein. Monoclonal antibodies to MHC class I (A, B, C) Experiments in the murine system have identified a N
and II (DR or DQ or DR, DP, DQ) molecules (10 mg/ml) were added to peptide spanning amino acids (aa) 67–98 as a major
microcultures containing 11 105 enriched T cells and 51 104 irradiated
proliferative epitope in both H-2d and H-2k mice (Gi-antigen-presenting cells that were stimulated with purified N protein
raudon et al., 1991). A second murine epitope was lo-(15 mg/ml). A monoclonal antibody specific for I-ab (10 mg/ml) was used
as a control (control aby). The induced proliferative responses of six cated between aa 457 and aa 525 in H-2d mice. Although
replicate wells per test group were measured by [3H]thymidine incorpo- the peptides used in the present study do not directly
ration after 7 days. Percentage inhibition is shown above the bar and correspond to the murine peptides, both of these regions
was calculated using the proliferative response to N protein as base-
were recognized by a number of vaccinated and naturallyline. (A) Donor A; (B) donor E.
infected humans. Two cytotoxic T-cell epitopes, 52–59
and 81–88, have previously been mapped in H-2k mice
(Beauverger et al., 1993). Peptides used in this studynated and the naturally infected individuals. Most immu-
nogenic T-cell determinants recognized by ⁄50% of do- and corresponding to peptides 51–70 and 83–102 were
stimulatory for 57 and 43%, respectively, of the individualsnors were located in the C-terminal half of the N (Fig. 4).
In vivo, the 60-kDa N is cleaved by a trypsin-like protease tested. An additional CTL epitope, 281–289, was identi-
fied in H-2k mice and was shown to sensitize P815 cellsnear the C terminus to yield proteins of 12 and 48 kDa
(Giraudon et al., 1988). It is possible that the 12-kDa to CTL lysis to the same level as cells transfected with
measles N alone (Beauverger et al., 1993). The corre-fragment (containing the C-terminal 150 amino acids of
the N protein) is preferentially processed by antigen- sponding peptide in this study, 271–290, was stimulatory
for 79% of all donors tested and was one of the two mostpresenting cells and this leads to the immunodominance
of this region of the protein. Interestingly, the greatest frequently recognized N peptides examined.
Natural measles virus infection imparts lifelong immu-degree of amino acid variability among wild-type mea-
sles viruses was previously shown to be within the C- nity against subsequent disease development whereas
vaccination with live attenuated measles vaccine doesterminal 125 amino acids of the N (Rota et al., 1994; Rima
et al., 1995; Taylor et al., 1991). Variation between vaccine not always result in enduring protection (Mathias et al.,
1989; Markowitz et al., 1990). A number of vaccineesand wild-type strains of measles in this region can ex-
ceed 10% at the amino acid level. This is in contrast to seroconvert but later become susceptible to both infec-
tion and disease. Since waning immunity is observedwhat has been seen in Neisseria meningitidis in which
most T-cell epitopes were located in conserved regions only in the vaccinated population, it seems likely that
the immune response to attenuated virus differs eitherof the Opa proteins (Wiertz et al., 1996). Experiments to
investigate the effects of measles wild-type sequence qualitatively or quantitatively from the response to wild-
type virus during an acute infection. Analysis of patternsvariation on cellular immune recognition in vaccinated
subjects are in progress. Preliminary results indicate that of peptide reactivity among vaccinated and naturally in-
fected groups in this study identified three regions ofsome of these individuals fail to give a significant prolifer-
ative response to wild-type variants of stimulatory vac- greatest difference between the two groups. Notably,
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FIG. 3. Antibodies to HLA DR inhibit proliferation of donor lymphocytes to N peptides. Monoclonal antibodies to HLA DR (DR) or DQ (DQ)
molecules (10 mg/ml) were added to microcultures containing 1 1 105 enriched T cells and 5 1 104 irradiated antigen-presenting cells that were
stimulated with the indicated peptide (10 mM). A monoclonal antibody specific for Iab (10 mg/ml) was used as a control (control aby). Little to no
inhibition was seen after treatment with control antibody. The induced proliferative responses of six replicate wells per test group were measured
by [3H]thymidine incorporation after 7 days. Percentage inhibition was calculated using the proliferative response to the indicated peptide (peptide)
as baseline. (A) Donor A, (B) donor E.
100% of naturally infected donors responded to peptides tory mucosa, differences in peptide response patterns
could be attributable to alternate processing of peptides221–240 and 237–256 whereas only 37.5% of vaccinated
donors had a significant proliferative response to these by antigen-presenting cells present at the site of inocula-
tion (macrophages vs dendritic cells). Nonetheless, pep-peptides. Also of interest is peptide 1–17, to which 62%
of vaccinated donors and none of the naturally infected tides recognized by naturally infected individuals but not
by vaccinated donors will provide a starting point fordonors responded. When interpreting these data, it is
important to note the relatively small number of donors investigations into the induction of lifelong versus tran-
sient immunity to measles.and HLA molecules (8 DR and 5 DQ alleles) represented
in this study. Furthermore, there is a skewed representa- Peptides 271–290, 367–386, 400–420, and 483–502
appear to be common major stimulatory regions in bothtion of DR13 in the vaccinated group. Additional donors
and a broader representation of HLA DR and DQ alleles vaccinated and naturally infected donors. Over 70% of all
donors examined gave significant proliferative re-are needed to determine if these peptide recognition
biases remain constant within these two groups. Further- sponses to these peptides. The variety of MHC class II
molecules associated with reactivity to these and othermore, because vaccine virus is delivered intramuscularly
but natural disease results from infection of the respira- cross-reactive peptides identified in this study suggests
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FIG. 4. Cumulative percentages of vaccinated and naturally infected donors who responded to measles N peptides. The total cumulative percentage
is scored out of a possible 200% for the two groups (vaccinated and naturally infected). Upper figure shows a similarity plot for the predicted N of
50 wild-type measles strains. The degree of deflection from the horizontal line indicates the degree of heterogeneity present within a sliding, 5-
amino-acid window.
that these peptides could be broadly recognized within indicate that different MHC molecules can interact with
the same sequence in the peptide. It is also possiblean HLA diverse population. Because immune responses
tend to be haplotype specific, MHC restriction is a poten- that some of the peptides tested contained different or
overlapping determinants that were recognized by dispa-tially limiting factor in vaccine strategies. Ideally, candi-
date peptide vaccines would consist of B-cell epitopes rate MHC molecules. A number of peptides with the abil-
ity to bind multiple MHC alleles have been describedcombined with multiple T-cell epitopes (helper and cyto-
toxic) that are recognized by a broad range of MHC allo- (Sinigaglia et al., 1988; McCarthy et al., 1993; Roche et
al., 1996; Kilgus et al., 1991). Use of chimeric moleculestypes.
Three B-cell epitopes have been identified on the mea- containing multiple well-characterized T- and B-cell epi-
topes or genetic alteration of attenuated vaccine virus tosles virus N (Giraudon et al., 1988; Buckland et al., 1989).
The first site which was identified on all measles virus enhance critical T-cell responses may eventually lead to
the development of a vaccine candidate that can morestrains studied was located between aa 122 and aa 150.
Two additional epitopes were identified at the C terminus closely model the patterns of immune response elicited
by wild-type virus.of the protein between aa 457 and 476 and between aa
519 and 525 and reactivity of the monoclonal antibodies
defining these sites varied with the virus isolate. Thus, ACKNOWLEDGMENTS
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T cells are generally from 9 to 16 amino acids in length.
T-cell epitopes may contain certain ‘‘core regions’’ that
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